PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumours and this therapy seems more effective in the biochemical and volume control of disease than SSA. We investigated the role of medical therapy with SSA and PRRT in patients with well and moderately differentiated neuroendocrine tumours. We evaluated 55 patients with well or moderately differentiated neuroendocrine tumours; 31 patients with either metastatic, unresectable or functioning tumours were treated with SSAs. Ten of them with metastatic disease or unresectable tumours, all with increased uptake on Octreoscan, underwent PRRT with 90Y or 177Lu. SSA allowed biochemical control of hormone secretion in all patients but one refractory carcinoid syndrome; six patients treated with PRRT showed minor or partial response, three had stable disease, one had progression. Three of the six patients with response to PRRT had further progression with a mean PFS of 12.7 months. Medical treatment with SSA allowed control of hormone secretion in the majority of patients. PRRT allowed minor or partial response of disease in a high proportion of treated patients. However, among these, a relatively high proportion of patients had further progression of disease.
30 Apr - 04 May 2011
European Society of Endocrinology